Lysyl oxidase-like 1 predicts the prognosis of patients with primary glioblastoma and promotes tumor invasion
Humans
Glioblastoma
/ pathology
Epithelial-Mesenchymal Transition
/ genetics
Prognosis
Neoplasm Invasiveness
Brain Neoplasms
/ pathology
Cell Line, Tumor
Nomograms
Scavenger Receptors, Class E
/ metabolism
Male
Tumor Microenvironment
Female
Amino Acid Oxidoreductases
/ genetics
Cell Proliferation
Biomarkers, Tumor
/ metabolism
Gene Expression Regulation, Neoplastic
Protein-Lysine 6-Oxidase
/ metabolism
Isocitrate Dehydrogenase
/ genetics
Glioblastoma
Invasion
LOXs
Nomogram
Prognosis
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2024
2024
Historique:
received:
30
11
2023
accepted:
25
05
2024
medline:
9
7
2024
pubmed:
9
7
2024
entrez:
9
7
2024
Statut:
epublish
Résumé
Lysyl oxidase enzymes (LOXs), as extracellular matrix (ECM) protein regulators, play vital roles in tumor progression by remodeling the tumor microenvironment. However, their roles in glioblastoma (GBM) have not been fully elucidated. The genetic alterations and prognostic value of LOXs were investigated GBM patients with altered LOXs had poor survival. Upregulated LOXs were found in IDH1-wildtype and mesenchymal (not Loxl1) GBM subtypes, promoting ECM receptor interactions in GBM. The Loxl1-based nomogram and the PRSM showed high accuracy, reliability, and net clinical benefits. Loxl1 expression was related to tumor invasion and immune infiltration (B cells, neutrophils, and dendritic cells). Loxl1 knockdown suppressed GBM cell proliferation and invasion by inhibiting the EMT pathway (through the downregulation of N-cadherin/Vimentin/Snai1 and the upregulation of E-cadherin). The Loxl1-based nomogram and PRSM were stable and individualized for assessing GBM patient prognosis, and the invasive role of Loxl1 could provide a promising therapeutic strategy.
Sections du résumé
Background
UNASSIGNED
Lysyl oxidase enzymes (LOXs), as extracellular matrix (ECM) protein regulators, play vital roles in tumor progression by remodeling the tumor microenvironment. However, their roles in glioblastoma (GBM) have not been fully elucidated.
Methods
UNASSIGNED
The genetic alterations and prognostic value of LOXs were investigated
Results
UNASSIGNED
GBM patients with altered LOXs had poor survival. Upregulated LOXs were found in IDH1-wildtype and mesenchymal (not Loxl1) GBM subtypes, promoting ECM receptor interactions in GBM. The Loxl1-based nomogram and the PRSM showed high accuracy, reliability, and net clinical benefits. Loxl1 expression was related to tumor invasion and immune infiltration (B cells, neutrophils, and dendritic cells). Loxl1 knockdown suppressed GBM cell proliferation and invasion by inhibiting the EMT pathway (through the downregulation of N-cadherin/Vimentin/Snai1 and the upregulation of E-cadherin).
Conclusion
UNASSIGNED
The Loxl1-based nomogram and PRSM were stable and individualized for assessing GBM patient prognosis, and the invasive role of Loxl1 could provide a promising therapeutic strategy.
Identifiants
pubmed: 38978755
doi: 10.7717/peerj.17579
pii: 17579
pmc: PMC11229686
doi:
Substances chimiques
LOXL1 protein, human
EC 1.4.3.-
Scavenger Receptors, Class E
0
Amino Acid Oxidoreductases
EC 1.4.-
Biomarkers, Tumor
0
Protein-Lysine 6-Oxidase
EC 1.4.3.13
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e17579Informations de copyright
© 2024 Yuan et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.